Acute ischemic stroke. Cerebral infarction, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Resveratrol capsules containing 250 mg of resveratrol and 10 mg of grape skin extract three times a day, equivalent to 750 mg of resveratrol and 30 mg of grape skin
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Willingness to cooperate and complete the informed consent form by the patient or legal guardian, patients aged 18-85 years, body mass index = 35 kg/m2, starting the intervention within 24 hours after being admitted to the ICU and not spending More than 24 hours from the time of disease diagnosis until the time of entering the study, the severity of stroke based on the NIHSS standard is higher than 4, the patient's GCS at the time of visit is higher than 3, feeding by enteral feeding method, receiving at least 80 percent of the prescribed formula during the first 48 hours, none Absolute contraindications for enteral feeding (permanent ileus, ischemia of the digestive tract, bilious or continuous vomiting and mechanical obstruction), the possibility of hospitalization in the intensive care unit (ICU) for 28 days, not suffering from hepatic encephalopathy and liver cirrhosis, not suffering from metastatic cancer, not having infection and sepsis, not having AIDS (HIV), not having hepatitis, not receiving supplements or formulas that strengthen the immune system, including arginine, glutamine, colostrum, vitamins C and E, selenium, zinc or Omega-3 fatty acids or resveratrol supplement during the last 30 days before the start of the intervention, not suffering from allergies or intolerance to the enteral formula used in the present study and resveratrol supplement, non-participation in other interventional studies. No company in the past 30 days in other clinical trial studies at the same time as the present study
Exclusion criteria
Exclusion criteria: Pregnancy, lactation, intracranial hemorrhage, history of previous stroke, consumption of any natural food containing resveratrol within 48 hours before the onset of stroke, patients who received rtPA, more than 24 hours from onset of symptoms, seizure at onset Stroke, intracranial hemorrhage, symptoms suggestive of subarachnoid hemorrhage, rapid recovery or partial symptoms, stroke severity based on NIHSS criteria less than 4, patient suffering from dementia before stroke
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL-1ß gene expression. Timepoint: At the beginning of the study and 28th day. Method of measurement: Real-time PCR.;Stroke severity score NIHSS: National Institutes of Health Stroke Scale. Timepoint: At the beginning of the study and 28th day. Method of measurement: Physical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| NLRP3 gene expression. Timepoint: At the beginning of the study and 28th day. Method of measurement: Real-time PCR.;ASC gene expression. Timepoint: At the beginning of the study and 28th day. Method of measurement: Real-time PCR.;Caspase-1gene expression. Timepoint: At the beginning of the study and after twenty-eight days of intervention. Method of measurement: Real-time PCR.;Serum levels of IL-1ß. Timepoint: At the beginning of the study and after twenty-eight days of intervention. Method of measurement: By ELISA kit.;Serum levels of IL-6. Timepoint: At the beginning of the study and after twenty-eight days of intervention. Method of measurement: By ELISA kit.;Serum total antioxidant capacity. Timepoint: At the beginning of the study and after twenty-eight days of intervention. Method of measurement: Colorimetric.;Serm malondialdehyde (MDA) level. Timepoint: At the beginning of the study and after twenty-eight days of intervention. Method of measurement: Colorimetric.;Barthel Index. Timepoint: 28 days after the end of the intervention and 90 days after the end of the intervention. Method of measurement: Based on specific forms that the patient or his / her companions will be asked by phone or in person.;Modified Rankin Scale (MRS). Timepoint: 28 days after the end of the intervention and 90 days after the end of the intervention. Method of measurement: Based on specific forms that the patient or his / her companions will be asked by phone or in person.;APACHE II score. Timepoint: At the beginning of the study and after twenty-eight days of intervention. Method of measurement: in this study, APACHEII questionnaire will be complimented.;SOFA score. Timepoint: At the beginning of the study and after twenty-eight days of intervention. Method of measurement: in this study, SOFA questionnaire will be complimented.;NUTRIC score. Timepoint: At the beginning of the study and after twenty-eight days of intervention. Method of measurement: in this study, NUTRIC score questio | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzad shidfar
Iran University of Medical Sciences
Outcome results
None listed